Erratum to: In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain [J Antimicrob Chemother, 70, (2015), (2311-2315)] doi: 10.1093/jac/dkv092;In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in spain

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2311-2315

  Reigadas, E ^a,b,c   Alcala L ^a,c,d   Marin M ^a,b,c,d   Pelaez T ^a,b,c,d   Martin, A ^a,c   Iglesias, C ^a,d   Bouza, E ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antimicrobial susceptibility; C. difficile; Fidaxomicin; Ribotype

Indexed keywords

CLINDAMYCIN; FIDAXOMICIN; METRONIDAZOLE; MOXIFLOXACIN; RIFAXIMIN; SUROTOMYCIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; SPAIN; ADOLESCENT; ADULT; AGED; CHILD; CLASSIFICATION; CLOSTRIDIUM INFECTION; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; RIBOTYPING; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; GENOTYPE; HUMANS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PEPTIDES, CYCLIC; RIBOTYPING; SPAIN; YOUNG ADULT;

EID: 84939495485     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw267     Document Type: Erratum

References (30)

1. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficileassociated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5: 549-57.
2. McFarland LV, Surawicz CM, Rubin M et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50.
3. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26.
4. Mascio CT, Mortin LI, Howland KT et al. In vitro and in vivo characterization of CB-183, 315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 2012; 56: 5023-30.
5. Citron DM, Tyrrell KL, Merriam CV et al. In vitro activities of CB-183, 315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 2012; 56: 1613-5.
6. Snydman DR, Jacobus NV, McDermott LA. Activity of a novel cyclic lipopeptide, CB-183, 315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 2012; 56: 3448-52.
7. Clinical and Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Eighth Edition: Approved Standard M11-A8. CLSI, Wayne, PA, USA, 2012.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
9. Stubbs SL, Brazier JS, O'Neill GL et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-3.
10. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
11. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-9.
12. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New Engl J Med 2011; 364: 422-31.
13. Babakhani F, Gomez A, Robert N et al. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60: 1213-7.
14. Chesnel L. Treatment of CDAD with oral CB-183 315: time to recurrence, relapse and re-infection rates compared with vancomycin. Clin Microbiol Infect 2012; 18: Suppl 3: 380.
15. Mascio CT, Chesnel L, Thorne G et al. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis and Enterococcus faecium. Antimicrob Agents Chemother 2014; 58: 3976-82.
16. Sanders I, Harmanus C, Debast S et al. Antibiotic susceptibility of surotomycin and five other antibiotics against Clostridium difficile isolates, collected at a pan-European survey in 2008 (n=119). In: Abstracts of the Twenty-fourth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, 2014, Abstract P0792. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
17. Tickler IA, Goering RV, Whitmore JD et al. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States: 2011-2013. Antimicrob Agents Chemother 2014; 58: 4214-8.
18. Alcala L, Martin A, Marin M et al. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin Microbiol Infect 2012; 18: E204-13.
19. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-49.
20. Alcalá L, Reigadas E, Marín M et al. Multicenter study of Clostridium difficile infection in Spain: an update of the underdiagnosis of Clostridiumdifficile infection in awhole nation. In: Abstracts of the Twenty-fourth European Congress of Clinical Microbiology and Infectious Diseases, 2014. Abstract P0741. European Society of Clinical Microbiology and Infectious Diseases, Barcelona, Spain.
21. Spigaglia P, Barbanti F, Mastrantonio P. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 2011; 66: 2227-34.
22. Hecht DW, GalangMA, Sambol SP et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from1983 to 2004. Antimicrob Agents Chemother 2007; 51: 2716-9.
23. O'Connor JR, Galang MA, Sambol SP et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008; 52: 2813-7.
24. Miller MA, Blanchette R, Spigaglia P et al. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol 2011; 49: 4319-21.
25. Huang H, Weintraub A, Fang H et al. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 2010; 16: 633-5.
26. Kim J, Kang JO, Pai H et al. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Int J Antimicrob Agents 2012; 40: 24-9.
27. Curry SR, Marsh JW, Shutt KA et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48: 425-9.
28. Debast SB, Bauer MP, Sanders IM et al. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. J Antimicrob Chemother 2013; 68: 1305-11.
29. Herpers BL, Vlaminckx B, Burkhardt O et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48: 1732-5.
30. Lu CL, Liu CY, Liao CH et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010; 35: 311-2.